Lung cancer has a strong etiologic association with cigarette smoking. Nicotine, a major component in tobacco smoke, functions as a survival agonist that inhibits apoptosis following various stresses. However, the mechanism of action remains elusive. Mcl-1, a major antiapoptotic protein of the Bcl2 family, is extensively expressed in both small cell and non-small cell lung cancer cells, suggesting that Mcl-1 may be a therapeutic target of patients with lung cancer. Here, we found that nicotine induces Mcl-1 phosphorylation through activation of extracellular signal-regulated kinase 1/2 in association with increased chemoresistance of human lung cancer cells. 
Introduction
Lung cancer is the main cause of cancer deaths in both sexes with an annual mortality rate of 91% (1) . Cigarette smoking is by far the most important risk factor in the development of lung cancer. For example, cigarette smokers have a 20-fold higher relative risk of developing lung cancer compared with nonsmokers (1) . Ninety percent of all lung cancers are caused by cigarette smoke including second hand smoke (2) . Cigarette smoke contains about 4,000 chemicals, 55 of which have been evaluated as carcinogens (3) . Nicotine is a major component in tobacco that exists at high concentrations (∼90-1,000 nmol/L) in the blood of smokers (4) . Nicotine functions as a survival agonist to inhibit apoptosis induced by diverse stimuli, including chemotherapeutic drugs (5) . However, the intracellular signal transduction mechanism(s) involved in nicotine suppression of apoptosis remains enigmatic.
Bcl-2 family members are key regulators of apoptotic cell death and deregulation of these proteins could be oncogenic (6, 7) . There are at least 20 members in the Bcl2 family, all of which share at least one BH (Bcl-2 homology) domain (8) . Recent studies suggest that prognosis of lung cancer is closely linked to the Bcl-2 family members (9-11). Our previous studies have shown that nicotine induces Bcl2 phosphorylation at serine (S) 70 in association with prolonged cell survival (12) . We recently discovered that nicotine can also stimulate phosphorylation and inactivation of the proapoptotic proteins (i.e., Bad and Bax; refs. 13, 14) . However, whether other Bcl-2 family member(s), for example, Mcl-1, is involved in nicotine signal transduction pathways remains unclear. Mcl-1 is a major antiapoptotic member of the Bcl2 family, which is extensively expressed in various human lung cancer cells (15) . Mcl-1 is one unique member of the Bcl2 family because of its short half-life (30 minutes-3 hours in various cell types) and short-term prosurvival function, which probably relates to the presence of a long proline-, glutamic acid-, serine-, and threonine-rich (PEST) region upstream of the BH domain (16) (17) (18) (19) . Thus, the mechanism(s) to prolong the half-life of Mcl-1 protein is critical for its long-term survival function.
Mcl-1 protein can be phosphorylated at multiple sites that distinctly regulate Mcl-1 protein turnover. For example, extracellular signal-regulated kinase (ERK)1/2-mediated T163 site phosphorylation enhances the half-life and antiapoptotic function of Mcl-1 (20, 21) . In contrast, S159 phosphorylation by GSK-3β facilitates Mcl-1 ubiquitination and degradation to reduce its survival activity (22) . Additionally, the Cdk1/2-mediated S64 site phosphorylation increases the antiapoptotic function but has no effect on its half-life (16) . Since nicotine can activate ERK1/2 (1, 12) , which is a physiologic T163 site kinase of Mcl-1 (20) , in this study, we have shown that nicotine induces Mcl-1 phosphorylation at T163 through activation of ERK1/2, which leads to prolonged half-life of Mcl-1 with enhanced antiapoptotic function in human lung cancer cells.
Results

Nicotine Induces Mcl-1 Phosphorylation in Association with Prolonged Survival of Human Lung Cancer Cells
Mcl-1 is a major antiapoptotic member of Bcl2 family. Intriguingly, Mcl-1 is more widely expressed in human lung cancer cells, including small cell lung cancer and non-small cell lung cancer cells, than Bcl2 (Fig. 1A) (20) . To test whether nicotine-stimulated Mcl-1 phosphorylation occurs through ERK1/2, H1299 cells were treated with increasing concentrations of nicotine for 30 minutes. Phosphorylation of ERK1/2 was analyzed by Western blot using a phospho-specific ERK antibody as previously described (12) . Results reveal that nicotine induces phosphorylation and activation of ERK1/2 in a dose-dependent manner ( Fig. 2A) . Coimmunofluorescent staining using p-ERK and Mcl-1 antibodies shows that treatment of cells with nicotine significantly enhances the phosphorylated form of ERK1/2 (i.e., pERK) to colocalize with Mcl-1 (Fig. 2B) (Fig. 3A) . Intriguingly, nicotine enhances survival of cells expressing WT but not the cells expressing the T163A Mcl-1 mutant (Fig. 3B) . Nicotine has no additional survival activity in cells expressing T163E Nicotinic acetylcholine receptors, especially α7nAChR or β-adrenergic receptor, have been found to play an important role in nicotine signaling in human lung cancer cells (13) . Thus, α-bungartoxin, a noncompetent potent α7 nicotinic acetylcholine receptor-specific inhibitor (24) , and propranolol, a β-adrenergic receptor inhibitor (25) , were selected to test which type of receptor may be involved in nicotine/Mcl-1 signaling. H1299 cells were treated with nicotine in the presence or absence of increasing concentrations of propranolol or α-bungartoxin. Interestingly, propranolol but not α-bungartoxin can inhibit nicotine-induced activation of ERK1/2 as well as Mcl-1 phosphorylation in a dose-dependent manner (data not shown; Fig. 5A and B) . Functionally, propranolol also blocks nicotine-induced cell survival and promotes apoptosis following treatment with cisplatin (Fig. 5C ). These results reveal that nicotine-induced Mcl-1 phosphorylation may occur in a mechanism involving the upstream β-adrenergic receptor in human lung cancer cells.
Nicotine-Induced Mcl-1 Phosphorylation Enhances Mcl-1 Expression and Its Half-Life
To test whether nicotine affects Mcl-1 expression, H82 cells expressing low levels of endogenous Mcl-1 or H157 and H1299 cells expressing high levels of endogenous Mcl-1 were treated with increasing concentrations of nicotine for 3 hours. Results indicate that nicotine induces a dose-dependent increase of Mcl-1 expression in various lung cancer cells (Fig. 6A) . To further determine whether nicotine regulates the turnover rate of Mcl-1, the half-life of Mcl-1 was measured using the classic 35 S-methionine pulse-chase method as described (26) . H157 or H1299 cells were metabolically labeled with 
Mcl-1 Is a Required Target in Nicotine-Induced Survival of Human Lung Cancer Cells
To test whether Mcl-1 is a required target for nicotineinduced survival of human lung cancer cells, an RNAi approach was used. Recent studies have shown that transfection of cells with siRNA concentrations of >100 nmol/L frequently produces nonspecific off-target effects, and a concentration of 20 to 100 nmol/L only occasionally produces effects (28) . One group has reported that siRNA concentrations of 10 to 20 nmol/L generally do not exert nonspecific effects (29) (Fig. 7A) . Importantly, specific knockdown of Mcl-1 expression by RNAi significantly enhances apoptotic cell death following treatment with the chemotherapeutic drug cisplatin in the absence or presence of nicotine (Fig. 7B) . Nicotine had no significant survival effect on cells expressing Mcl-1 siR-NA, suggesting that Mcl-1 is a required target in nicotineinduced survival and/or chemoresistance of H1299 lung cancer cells. 
Discussion
The antiapoptotic Bcl2 family member Mcl-1 has been originally identified in the ML-1 human myeloid leukemia cell line which undergoes phorbol ester-induced differentiation (29) . Mcl-1 can be stimulated by multiple growth factors including interleukin (IL)-3, IL-5, IL-6, IL-7, granulocyte-macrophage colony-stimulating factor, vascular endothelial growth factor, α IFN, and epidermal growth factor (30) . A recent report and our findings indicate that Mcl-1 is extensively expressed in both small cell lung cancer and non-small cell lung cancer cells (Fig. 1A;  ref. 15) . Importantly, nicotine, a major component of cigarette smoke, can mimic growth factor(s) to simulate Mcl-1 phosphorylation, which is associated with enhanced chemoresistance of human lung cancer cells (Fig. 1 ). ERK1 and ERK2 are physiologic Mcl-1 kinases that can phosphorylate Mcl-1 at T163 site in the PEST region (amino acid 104-176; refs. 20, 31). Intriguingly, nicotine not only stimulates phosphorylation and activation of ERK1/ 2 but also facilitates the phosphorylated, active ERK1/2 to colocalize with Mcl-1 in cytoplasm ( Fig. 2A and B) . Because active ERK1 and ERK2 can directly phosphorylate the Mcl-1 protein isolated from human lung cancer H1299 cells (Fig. 2C ) and the specific MEK/ERK inhibitor PD98059 blocks nicotine-stimulated Mcl-1 phosphorylation (Fig. 4) , we propose that ERK1 and ERK2 function as nicotine-activated Mcl-1 kinases to phosphorylate Mcl-1 and regulate its activity in human lung cancer cells.
Genetic studies indicate that nicotine stimulates Mcl-1 phosphorylation exclusively at T163 site because only WT but not the T163A Mcl-1 mutant can be phosphorylated when cells were exposed to nicotine (Fig. 3A) . The nonphosphorylatable T163A Mcl-1 mutant displays less antiapoptotic activity than WT Mcl-1. Because nicotine only prolongs survival of cells expressing WT but not the T163A Mcl-1 mutant, this suggests that phosphorylation of Mcl-1 at T163 is essential for nicotineinduced Mcl-1 phosphorylation and survival. Moreover, a substitution of T163 with glutamate (E), which mimics T163 site phosphorylation in the PEST region, also enhances the antiapoptotic activity of Mcl-1 (Fig. 3) . These findings indicate that either the phosphomimetic mutation at T163 or nicotineinduced T163 site phosphorylation can enhance the survival activity of Mcl-1. Thus, the T163 site should be a critical target for nicotine to positively regulate the antiapoptotic function of Mcl-1.
In addition to the nicotine acetylcholine receptors, high levels of β-adrengernic receptor have been found to be expressed in human lung cancer cells (32) . Mounting evidence now indicates that nicotine can function as a β-adrengernic receptor agonist and its effect is abrogated by propranolol (a β-adrengernic receptor inhibitor; refs. 25, 33) . It has been reported that ERK1 and ERK2 are the signal downstream components in nicotine/β-adrenergic receptor signaling pathway (34) (35) (36) . Importantly, ERK1 and ERK2 are physiologic Mcl-1 kinases (20) . Because treatment of cells with β-adrenergic receptor inhibitor (propranolol) not only suppresses nicotine-stimulated ERK1/2 activation (Fig. 5A ) but also inhibits Mcl-1 phosphorylation (Fig. 5B) , the β-adrenergic receptor should be linked to nicotine-stimulated Mcl-1 phosphorylation through ERK activation. Thus, the β-adrenergic receptor may function as the major upstream receptor in nicotine-stimulated ERK/Mcl-1 survival signal pathway. Importantly, inhibition of nicotine-induced ERK activation and Mcl-1 phosphorylation by propranolol suppresses nicotine-stimulated survival and enhances apoptotic cell death (Fig. 5) . Thus, propranolol may have the potential to be developed as a clinically useful drug that specifically targets the β-adrenergic receptor to block nicotine-stimulated survival signal pathway in patients with lung cancer expressing high levels of β-adrenergic receptor and Mcl-1.
Mcl-1 protein is rapidly degraded in response to cell death signals and is immediately reinduced by survival stimuli (30) . Mcl-1 has a very short half-life (i.e., 30 minutes-3 hours) in various cells (16) (17) (18) (19) . Because nicotine can induce Mcl-1 phosphorylation at T163 site through activation of ERK1/2 (Figs. 1-3 ), this may positively regulate Mcl-1 stability and expression level. As expected, nicotine not only markedly prolongs the half-life of Mcl-1 from 1.5 to 2.2 hours to 5 to 6 hours but also upregulates its expression level in various human lung cancer cells (Fig. 6) . This supports the notion that nicotine-stimulated Mcl-1 phosphorylation at T163 may prevent Mcl-1 from Mule-induced polyubiquitination and degradation, which could render Mcl-1 a longer half-life and long-term survival activity. H82 cells express very low levels of endogenous Mcl-1 (Fig. 1A) and exposure of H82 cells to nicotine upregulates Mcl-1 expression (Fig. 6A) . However, nicotine failed to protect the vector-only H82 cells from cisplatin treatment (Fig. 3B) . This consequence may result from the ability of cisplatin to block nicotineenhanced Mcl-1 expression in H82 cells (data not shown). In support of this, cisplatin has also been reported to facilitate Mule-mediated Mcl-1 degradation (27) . This may help explain why nicotine fails to protect H82 cells from cisplatin treatment.
Specific depletion of Mcl-1 from H1299 cells by RNAi blocks nicotine-stimulated survival and enhances sensitivity of human lung cancer cells to chemotherapeutic drug, cisplatin (Fig. 7) . This indicates that Mcl-1 is an essential target for nicotine-induced survival and chemoresistance in human lung cancer cells. Thus, Mcl-1 should be a major target for development of new strategies for lung cancer treatment.
In summary, our studies show that nicotine promotes survival of human lung cancer cells in a novel mechanism by activating the antiapoptotic function of Mcl-1 via its phosphorylation. Nicotine activates ERK1/2 through the upstream β-adrenergic receptor, which can induce Mcl-1 phosphorylation at T163 site in the PEST region. Nicotine-induced Mcl-1 phosphorylation at T163 enhances the half-life of Mcl-1, which leads to its longterm survival function and/or chemoresistance of human lung cancer cells. Thus, disruption of the antiapoptotic function of Mcl-1 by blocking its T163 site phosphorylation may represent a new strategy for the treatment of tobacco-related cancer especially lung cancer and other malignancies that express Mcl-1.
Materials and Methods
Materials
Nicotine, propranolol, cisplatin, and VP-16 were purchased from Sigma. Purified ERK1 and ERK2 were obtained from Cell Lines, Plasmids, cDNA, Mutagenesis, and Transfections H23, H69, H82, H157, H358, H460, and H1299 cells were maintained in RPMI 1640 with 10% fetal bovine serum. A549 cells were maintained in F-12K medium with 10% fetal bovine serum. WT Mcl-1 cDNA was cut from Mcl-1 cDNA/pcDNA3.1/ V5-His-TOPO construct using BamHI and XbaI restriction enzymes. The Mcl-1 cDNA insert was cloned in pUC19. Nucleotides corresponding to threonine (T) 163 residue was substituted to create a conservative alteration to alanine (A) or glutamic acid (E). The 5′ phosphorylated mutagenic primers for Mcl-1 mutants were synthesized as follow: T163A, 5′-GTC ACT ACC CTC GGC GCC GCC GCC AGC-3′; T163E, 5′-GTC ACT ACC CTC GGA GCC GCC GCC AGC AG-3′. The WT-Mcl-1/pUC19 construct was used as the target plasmid, which contains a unique NdeI restriction site for selection against the unmutated plasmid. The NdeI selection primer is 5′-GAG TGC ACC ATG GGC GGT GTG AAA-3′. The nonphosphorylatable (T163A) and the phosphomimetic (T163E) Mcl-1 mutants were created using a site-directed mutagenesis kit (Clontech) according to the manufacturer's instructions. Each single mutant was confirmed by sequencing of the cDNA and was then cloned into the pCIneo (Promega) mammalian expression vector. The pCIneo plasmids containing WT, T163A, or T163E were transfected into H82 cells using Lipofectamine 2000 (Invitrogen). Clones stably expressing WT, T163A, or T163E were selected in medium containing G418 (0.8 mg/mL). The expression levels of exogenous Mcl-1 were compared by Western blot analysis using a Mcl-1 antibody. Three separate clones for each mutant expressing similar amounts of exogenous Mcl-1 were selected for analysis.
Metabolic Labeling, Immunoprecipitation, and Western Blot Analysis
Cells were washed with phosphate-free RPMI and metabolically labeled with 32 P-orthophosphoric acid for 90 min. After agonist or inhibitor addition, cells were washed with ice-cold PBS and lysed in detergent buffer. Mcl-1 was immunoprecipitated and subjected to 10% SDS-PAGE, transferred to a nitrocellulose membrane, and exposed to Kodak X-omat film at −80°C. Mcl-1 phosphorylation was determined by autoradiography. The same filter was then probed by Western blot analysis with a Mcl-1 antibody and developed by using an enhanced chemiluminescence kit (Amersham) as described previously (12, 14) .
Preparation of Cell Lysates
Cells were washed with 1× PBS and resuspended in ice-cold EBC buffer [0.5% NP40, 50 mmol/L Tris (pH 7.6), 120 mmol/L NaCl, 1 mmol/L EDTA, and 1 mmol/L β-mercaptoethanol] with a cocktail of protease inhibitors (EMD Biosciences). Cells were lysed by sonication and centrifuged at 14,000 × g for 10 min at 4°C. The resulting supernatant was collected as the total cell lysate.
Immunofluorescence
The cells were washed with 1× PBS, fixed with methanol and acetone (1:1) for 5 min, and then blocked with 10% normal mouse or rabbit serum for 20 min at room temperature. Cells were incubated with a mouse or rabbit primary antibody for 90 min. After washing, samples were incubated with Alexa 488 (green)-conjugated anti-mouse or Alexa 594 (red)-conjugated anti-rabbit secondary antibodies for 60 min. Cells were washed with 1× PBS and observed under a fluorescent microscope (Zeiss). Pictures were taken and colored with the same exposure setting for each experiment. Individual green-and red-stained images derived from the same field were merged using Openlab 3.1.5 software from Improvision, Inc.
Mcl-1 Phosphorylation by ERK1 and ERK2 In vitro
Mcl-1 was immunoprecipitated from lysates isolated from H1299 cells and incubated with purified, activated ERK1 or ERK2 enzyme (0. S-labeled Mcl-1 was immunoprecipitated by using Mcl-1 antibody. The samples were subjected to SDS/ 10-20% PAGE. The half-life (t 1/2 ) of Mcl-1 was determined by electronic autoradiography as described (26) .
RNA Interference
Human Mcl-1 siRNA (GAAGACCAUAAACCAAGAAtt) was purchased from Santa Cruz Biotechnology. H1299 cells were transfected with Mcl-1 siRNA using Lipofectamine 2000 (Invitrogen). A control siRNA (nonhomologous to any known gene sequence) was used as a negative control. The levels of Mcl-1 expression were analyzed by Western blot. Specific silencing of the targeted Mcl-1 gene was confirmed by at least three independent experiments.
Cell Viability Assay
Apoptotic and viable cells were detected using an ApoAlert Annexin-V kit (Clontech) according to the manufacturer's instructions. The percentage of annexin V low (i.e., viable) or annexin V high (i.e., apoptotic) cells was determined using the data obtained by fluorescence-activated cell sorter analysis as described (14) . Cell viability was also confirmed using the trypan blue dye exclusion method.
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